参考文献/References:
[1] Sciuto R, Romano L, Rea S, et al. Natural history and clinical outcome of differentiated thyroid carcinoma:a retrospective analysis of 1503 patients treated at a single institution. Ann Oncol, 2009, 20(10):1728-1735.
[2] Muresan MM, Olivier P, Leclere J, et al. Bone metastases from differentiated thyroid carcinoma. Endocr Relat Cancer, 2008, 15(1):37-49.
[3] Mihailovic JM, Stefanovic LJ, Malesevic MD, et al. Metastatic differentiated thyroid carcinoma:clinical management and outcome of disease in patients with initial and late distant metastases. Nucl Med Commun, 2009, 30(7):558-564.
[4] Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma:benefits and limits of radioiodine therapy. J Clin Endocrinol Metab, 2006, 91(8):2892-2899.
[5] Schlumberger M, Tubiana M. De Vathaire F, et al. Long-term results of treatment of 283 patients with lung ang bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab, 1986, 63(4):960-967.
[6] Sugltani I, Fujimoto Y, Yamamoto N, et al. Papillary thyroid carcinoma with distant metastases:survival predictors and the importance of local control. Surgery, 2008, 143(1):35-42.
[7] Baitei EY, Zou M, A1-Mohanna F, et al. Aberrant BRAF splicingas an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma. J Pathol, 2009, 217(5):707-715.
[8] Kogai T, Sajid-Crockett S, Newmarch LS, et al. Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid ceils and human papillary thyroid cancer cells. J Endocrinol, 2008, 199(2):243-252.
[9] Ahn SH, Henderson Y, Kang Y, et al. An orthotopic model of papillary thyroid carcinoma in athymic nude mice. Arch Otolaryngol Head Neck Surg, 2008, 134(2):190-197.
[10] Younes MN, Kim S, Yigitbasi OG, et al. Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Mol Cancer Ther, 2005, 4(8):1146-1156.
[11] Schweppe RE, Kerege AA, Sharma V, et al. Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition. Thyroid, 2009, 19(8):825-835.
[12] Cheng SP, Yin PH, Chang YC, et al. Differential roles of leptin in regulating cell migration in thyroid cancer cells. Oncol Rep, 2010, 23(6):1721-1727.
[13] Schweppe RE, Klopper JP, Korch C, et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endoerinol Metab, 2008, 93(11):4331-4341.
[14] Klopper JP, Berenz A, Hays WR, et al. In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma. Clin Cancer Res, 2008, 14(2):589-596.
[15] Kim S, Yazici YD, Calzada G, et al. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther, 2007, 6(6):1785-1792.
[16] Nahari D, Satchi-Fainaro RS, Chen M, et al. Tumor cytotoxicity and endothelial Rac inhibition induced by TNP-470 in anaplastic thyroid cancer. Mol Cancer Ther, 2007, 6(4):1329-1337.
[17] Lin X, Zhu B, Liu Y, et al. Follicular thyroid carcinoma invades venous rather than lymphatic vessels. Diagn Pathol, 2010, 5:8.
[18] Hombaeh-Klonisch S, Bialek J, Radestock Y, et al. INSL3 has tumorpromoting activity in thyroid cancer. Int J Cancer, 2010, 127(3):521-531.
[19] Ereolino T, Lombardi A, Becherini L, et al. The Y606C RET mutation causes a receptor gain of function. Clin Endocrinol (Oxt), 2008, 69(2):253-258.
[20] Quidville V, Segond N, Tebbi A, et al. Anti-tumoral effect of a celecoxib low dose on a model of human medullary thyroid cancer in nude mice. Thyroid, 2009, 19(6):613-621.
[21] Vitagliano D, De Falco V, Tamburrino A, et al. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Endocr Relat Cancer, 2010, 18(1):1-11.
[22] Chen MC, Yu CH, Wang SW, et al. Anti-proliferative effects of evodiamine on human thyroid eancer cell line ARO. J Cell Biochem, 2010, 110(6):1495-1503.
[23] Arcinas A, Yen TY, Kebebew E, et al. Cell surface and secreted protein profiles of human thyroid cancer cell lines reveal distinct glycoprotein patterns. J Proteome Res, 2009, 8(8):3958-3968.
[24] Hoffmann S, Rockenstein A, Ramaswamy A, et al. Retinoic acid inhibits angiogenesis and tumor growth of thyroid cancer cells. Mol Cell Endocrinol, 2007, 264(1-2):74-81.
[25] Fortin MA, Salnikov AV, Nestor M, et al. Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36:application to antibody tumour uptake studies. Eur J Nucl Med Mol Imaging, 2007, 34(9):1376-1387.
[26] Leux C, Guénel P. Risk factors of thyroid tumors:role of environmental and occupational exposures to chemical pollutants. Rev Epidemiol Sante Publique, 2010, 58(5):359-367.
[27] Alfano RW, Leppla SH, Liu S, et al. Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma. Mol Cancer Ther, 2010, 9(1):190-201.
[28] Hombach-Klonisch S, Bialek J, Radestock Y, et al. INSL3 has tumorpromoting activity in thyroid cancer. Int J Cancer, 2010, 127(3):521-531.
[29] Zatelli MC, Tagliati F, Amodio V, et al. Role of pituitary tumour transforming gene 1 in medullary thyroid carcinoma. Anal Cell Pathol (Amst), 2010, 33(5):207-216.
[30] Henderson YC, Ahn SH, Kang Y, et al. Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement. Clin Cancer Res, 2008, 14(15):4908-4914.
[31] Nucera C, Nehs MA, Mekel M, et al. A novel orthotopic mouse model of human anaplastic thyroid carcinoma. Thyroid, 2009, 19(10):1077-1084.
[32] Sehiff BA, MeMurphy AB, Jasser SA, et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res, 2004, 10(24):8594-8602.
[34] Zou M, Famulski KS, Parhar RS, et al. Microarray analysis of metastasis-associated gene expression profiling in a murine model of thyroid carcinoma pulmonary metastasis:identification of S100 A4(Mtsl) gene overexpression as a poor prognostic marker for thyroid carcinoma. J Clin Endocrinol Metab, 2004, 89(12):6146-6154.
[33] Kim S, Park YW, Schiff BA, et al. An orthotopic model of anaplastic thyroid carcinoma in athymic nude mice. Clin Cancer Res, 2005, 11(5):1713-1721.
相似文献/References:
[1]李盼丽,宋少莉.碘难治性分化型甲状腺癌靶向药物治疗进展[J].国际放射医学核医学杂志,2016,40(3):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
Li Panli,Song Shaoli.Radioactive iodine refractory differentiated thyroid cancer targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
[2]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[3]陈立,陈跃.分化型甲状腺癌骨转移诊断及疗效评价的核素显像研究进展[J].国际放射医学核医学杂志,2016,40(6):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
Chen Li,Chen Yue.Diagnosis and evaluation of curative effect progress of radionuclide imaging methods in differentiated thyroid cancer of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
[4]廖光星,冷志欣,肖国有.前列腺癌骨转移影像诊断方法研究进展[J].国际放射医学核医学杂志,2016,40(6):464.[doi:10.3760/cma.j.issn.1673-4114.2016.06.012]
Liao Guangxing,Leng Zhixin,Xiao Guoyou.Progress of imaging in the diagnosis of bone metastases of prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):464.[doi:10.3760/cma.j.issn.1673-4114.2016.06.012]
[5]张胤,陈跃.18F-氟化钠PET/CT诊断肿瘤骨转移应用进展[J].国际放射医学核医学杂志,2015,39(1):96.[doi:10.3760/cma.j.issn.1673-4114.2015.01.020]
Zhang Yin,Chen Yue.Application progress of 18F-NaF PET/CT in the diagnosis of neoplasm metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):96.[doi:10.3760/cma.j.issn.1673-4114.2015.01.020]
[6]惠金子,赵德善.Tg、TgAb及TSH在分化型甲状腺癌术前的预测分析[J].国际放射医学核医学杂志,2015,39(2):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
Hui Jinzi,Zhao Deshan.The prediction of risk of differentiated thyroid carcinoma with preoperative serum thyroid stimulating hormone, thyrogiobulin and antithyroglobulin antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
[7]徐金苹,袁德晓,张江虹,等.辐射诱导的外泌体在肿瘤细胞侵袭转移中的作用[J].国际放射医学核医学杂志,2015,39(2):144.[doi:10.3760/cma.j.issn.1673-4114.2015.02.009]
Xu Jinping,Yuan Dexiao,Zhang Jianghong,et al.The role of radiation-induced exosomes in tumor invasion and metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):144.[doi:10.3760/cma.j.issn.1673-4114.2015.02.009]
[8]刘斌,潘明志.BRAF基因突变对甲状腺乳头状癌诊治价值的研究进展[J].国际放射医学核医学杂志,2015,39(2):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
Liu Bin,Pan Mingzhi.Advances in value of BRAF gene mutation on the diagnosis and treatment of papillary thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
[9]刘雪辉,李洪均,于鸿煦.SPECT/CT融合显像对可疑骨转移灶的诊断效能[J].国际放射医学核医学杂志,2015,39(3):201.[doi:10.3760/cma.j.issn.1673-4114.2015.03.003]
Liu Xuehui,Li Hongjun,Yu Hongxu.Diagnostic efficacy of SPECT/CT fusion imaging in assessing possible bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):201.[doi:10.3760/cma.j.issn.1673-4114.2015.03.003]
[10]胡斌,王锦锋,毛秋粉.18F-FDG PET/CT显像在Tg阳性131I全身显像阴性的分化型甲状腺癌患者中的应用价值[J].国际放射医学核医学杂志,2015,39(3):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
Hu Bin,Wang Jinfeng,Mao Qiufen.The application value of 18F-FDG PET/CT in patients with differentiated thyroid cancer of high thyroglobulin level and negative 131I whole body scan[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
[11]陈志军,谭丽玲,王文俊,等.131I联合125I粒子治疗难治性甲状腺癌骨转移一例[J].国际放射医学核医学杂志,2017,41(1):76.[doi:10.3760/cma.j.issn.1673-4114.2017.01.015]
[12]邓玮玮,朱娅华,范敏,等.99TcmO4-全身显像联合颈胸SPECT/CT在DTC患者术后肺转移灶显影中的应用[J].国际放射医学核医学杂志,2018,(3):207.[doi:10.3760/cma.j.issn.1673-4114.2018.03.003]
Deng Weiwei,Zhu Yahua,Fan Min,et al.Effectiveness of 99Tcm-pertechnetate whole body scan with neck and chest SPECT/CT for the detection of post-surgical pulmonary metastasis in differentiated thyroid carcinoma patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(6):207.[doi:10.3760/cma.j.issn.1673-4114.2018.03.003]